| Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma SJ Schuster, MR Bishop, CS Tam, EK Waller, P Borchmann, JP McGuirk, ... New England Journal of Medicine 380 (1), 45-56, 2019 | 3191 | 2019 |
| Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia JC Byrd, JR Brown, S O'Brien, JC Barrientos, NE Kay, NM Reddy, ... New England Journal of Medicine 371 (3), 213-223, 2014 | 1914 | 2014 |
| Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia JA Burger, A Tedeschi, PM Barr, T Robak, C Owen, P Ghia, O Bairey, ... New England Journal of Medicine 373 (25), 2425-2437, 2015 | 1694 | 2015 |
| Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia CS Tam, S O'Brien, W Wierda, H Kantarjian, S Wen, KA Do, DA Thomas, ... Blood, The Journal of the American Society of Hematology 112 (4), 975-980, 2008 | 913 | 2008 |
| Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia PA Thompson, CS Tam, SM O’Brien, WG Wierda, F Stingo, W Plunkett, ... Blood, The Journal of the American Society of Hematology 127 (3), 303-309, 2016 | 615 | 2016 |
| Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma T Munir, JR Brown, S O'Brien, JC Barrientos, PM Barr, NM Reddy, ... American journal of hematology 94 (12), 1353-1363, 2019 | 416 | 2019 |
| Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma CS Tam, MA Anderson, C Pott, R Agarwal, S Handunnetti, RJ Hicks, ... New England journal of medicine 378 (13), 1211-1223, 2018 | 413 | 2018 |
| Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study S O'Brien, JA Jones, SE Coutre, AR Mato, P Hillmen, C Tam, A Österborg, ... The Lancet Oncology 17 (10), 1409-1418, 2016 | 391 | 2016 |
| Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study JF Seymour, S Ma, DM Brander, MY Choi, J Barrientos, MS Davids, ... The Lancet Oncology 18 (2), 230-240, 2017 | 378 | 2017 |
| Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia P Blombery, MA Anderson, J Gong, R Thijssen, RW Birkinshaw, ... Cancer discovery 9 (3), 342-353, 2019 | 376 | 2019 |
| Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling JR McMullen, EJH Boey, JYY Ooi, JF Seymour, MJ Keating, CS Tam Blood, The Journal of the American Society of Hematology 124 (25), 3829-3830, 2014 | 371 | 2014 |
| A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study CS Tam, S Opat, S D'Sa, W Jurczak, HP Lee, G Cull, RG Owen, P Marlton, ... Blood, The Journal of the American Society of Hematology 136 (18), 2038-2050, 2020 | 365 | 2020 |
| Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study AR Mato, NN Shah, W Jurczak, CY Cheah, JM Pagel, JA Woyach, ... The Lancet 397 (10277), 892-901, 2021 | 349 | 2021 |
| The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL IW Flinn, P Hillmen, M Montillo, Z Nagy, Á Illés, G Etienne, J Delgado, ... Blood, The Journal of the American Society of Hematology 132 (23), 2446-2455, 2018 | 342 | 2018 |
| Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL CS Tam, J Trotman, S Opat, JA Burger, G Cull, D Gottlieb, R Harrup, ... Blood, The Journal of the American Society of Hematology 134 (11), 851-859, 2019 | 333 | 2019 |
| Phase 3 trial of ibrutinib plus rituximab in Waldenström’s macroglobulinemia MA Dimopoulos, A Tedeschi, J Trotman, R García-Sanz, D Macdonald, ... New England journal of medicine 378 (25), 2399-2410, 2018 | 323 | 2018 |
| Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions M Levade, E David, C Garcia, PA Laurent, S Cadot, AS Michallet, ... Blood, The Journal of the American Society of Hematology 124 (26), 3991-3995, 2014 | 320 | 2014 |
| The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism MA Anderson, J Deng, JF Seymour, C Tam, SY Kim, J Fein, L Yu, ... Blood, The Journal of the American Society of Hematology 127 (25), 3215-3224, 2016 | 319 | 2016 |
| Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study SJ Schuster, CS Tam, P Borchmann, N Worel, JP McGuirk, H Holte, ... The Lancet Oncology 22 (10), 1403-1415, 2021 | 302 | 2021 |
| Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL JR Brown, P Hillmen, S O’brien, JC Barrientos, NM Reddy, SE Coutre, ... Leukemia 32 (1), 83-91, 2018 | 260 | 2018 |
